{
    "clinical_study": {
        "@rank": "41982", 
        "acronym": "foodmagenpol", 
        "arm_group": [
            {
                "arm_group_label": "b-cryptoxanthin plus phytosterols", 
                "arm_group_type": "Active Comparator", 
                "description": "Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Fruit and milk based beverage not enriched"
            }
        ], 
        "brief_summary": {
            "textblock": "Regular consumption of a beverage containing \u03b2-cryptoxanthin (b-Cx) and plant sterols (Ps)\n      has been shown to exert a synergic effect in reducing cardiovascular risk and bone\n      remodeling markers (formation and resorption). The present project aims to assess the\n      influence of technological treatment and genetic variability on the bioavailability and the\n      health effects of the added components (Ps, b-Cx), in particular to their potential role in\n      prevalent disorders.In vitro and in vivo studies will be carried out to this effect. In\n      vitro and in vivo studies (human intervention study) will be performed and cardiovascular,\n      bone turnover and inflammation markers will be evaluated. Additionally, an in vitro colonic\n      fermentation model and cell cultures will be used to  explore anticarcinogenic effects and\n      potential cytotoxicity."
        }, 
        "brief_title": "Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypercholesterolemia", 
            "Osteoporosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Osteoporosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post-menopausal women; mild hypercholesterolemia\n\n        Exclusion Criteria:\n\n          -  Use of cholesterol lowering drugs, hormonal therapy, vitamin and herbs supplements\n             use"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065024", 
            "org_study_id": "AGL2012-39503-C02-02"
        }, 
        "intervention": {
            "arm_group_label": "b-cryptoxanthin plus phytosterols", 
            "intervention_name": "b-cryptoxanthin plus phytosterols", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": "Cryptoxanthin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "b-cryptoxanthin", 
            "plant sterols", 
            "serum Cholesterol", 
            "bone turnover markers"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Majadahonda (Madrid)", 
                    "country": "Spain", 
                    "state": "Madrid", 
                    "zip": "28222"
                }, 
                "name": "Hospital Universitario Puerta de Hierro-Majadahonda"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation", 
        "other_outcome": {
            "measure": "Intestinal transporters polymorphisms,", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "serum response of B-cryptoxanthin", 
                "safety_issue": "No", 
                "time_frame": "6 weeks of intervention"
            }, 
            {
                "measure": "Serum response of phytosterols", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065024"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Puerta de Hierro University Hospital", 
            "investigator_full_name": "Fernando Granado Lorencio", 
            "investigator_title": "dr Fernando Granado Lorencio", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum lipid profile", 
                "safety_issue": "No", 
                "time_frame": "6 weks of intervention"
            }, 
            {
                "measure": "bone resorption markers", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "interleukins", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Serum C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Bone formation markers", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Puerta de Hierro University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Puerta de Hierro University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}